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The relationship of polymorphisms in ABCC2 and SLCO1B3
with docetaxel pharmacokinetics and neutropenia: CALGB
60805 (Alliance)
Lionel D. Lewisa, Antonius A. Millerb, Kouros Owzarc, Robert R. Biesd,
Svetlana Markovae, Chen Jiangc, Deanna L. Kroetze, Merrill J. Egorinf,
Howard L. McLeodg, Mark J. Ratainh and for the Alliance for Clinical Trials
in Oncology
Docetaxel-related neutropenia was associated with
polymorphisms in the drug transporters ABCC2 and
SLCO1B3 in Japanese cancer patients. We hypothesized
that this association is because of reduced docetaxel
clearance, associated with polymorphisms in those genes.
We studied 64 US cancer patients who received a single
cycle of 75mg/m2 of docetaxel monotherapy. We found
that the ABCC2 polymorphism at rs-12762549 trended
to show a relationship with reduced docetaxel clearance
(P=0.048), but not with neutropenia. There was no
significant association of the SLCO1B3 polymorphisms
with docetaxel clearance or neutropenia. We conclude
that the relationship between docetaxel-associated
neutropenia and polymorphisms in drug transporters
identified in Japanese patients was not confirmed in
this cohort of US cancer patients. Pharmacogenetics and
Genomics 23:29–33 c 2012 Wolters Kluwer Health |
Lippincott Williams & Wilkins.
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Docetaxel, a semisynthetic taxane, is a cytotoxic agent
used widely for the treatment of breast, non-small-cell
lung and prostate cancer [1,2]. Previous pharmacokinetic
studies have evaluated both the erythromycin breath test
and genetic variation in drug-metabolizing enzymes and
transporters as determinants of the variability in doc-
etaxel clearance [3], but the major determinants of this
variability are incompletely defined. The differential
expression and function of polymorphic drug-metaboliz-
ing enzymes and/or transporters at the sites of drug
elimination could play a major role in this variability.
CYP3A4 and CYP3A5 are the primary enzymes involved
in hepatic oxidation of docetaxel to its major metabolite,
C-13-hydroxydocetaxel [3,4]. Hepatocellular uptake of
taxanes is regulated, at least in part, by the solute carrier
OATP1B3 (SLCO1B3; OATP8) [5], whereas the ATP-
binding cassette (ABC) transporters P-glycoprotein
(ABCB1) and MRP2 (ABCC2; cMOAT) [6] are involved
in the secretion of taxanes from the liver into the bile [7].
Neutropenia is the dose-limiting toxicity of docetaxel
[2,3]. To identify the genetic factors determining the risk
of docetaxel-induced neutropenia, Kiyotani et al. [8]
carried out a retrospective case–control study of 140
Japanese cancer patients who received docetaxel mono-
therapy, with 84 cases of grade 3/4 neutropenia and 56
controls (no neutropenia). The researchers identified
a strong association of grade 3/4 neutropenia with the
SNPs rs-12762549 in ABCC2 and rs-11045585 in
SCLO1B3. The presence of polymorphisms in both genes
yielded a seven-fold (95% confidence interval 2.95–
16.59) increase in the odds ratio for developing docetaxel-
associated neutropenia. As docetaxel-associated neutropenia
has been related to drug exposure (AUC) [3], we hypo-
thesized that rs-12762549 in ABCC2 and rs-11045585 in
SLCO1B3 are associated with reduced docetaxel clear-
ance and neutropenia.
We studied this hypothesis retrospectively in a subgroup
of patients who originally participated in CALGB 9871
(Alliance) [9] and who consented to have DNA collected
for studies of genes involved in docetaxel disposition and
pharmacodynamics. The protocol was approved by local
Institutional Review Boards. Details of the study design,
patient eligibility criteria, docetaxel regimen, neutropenia
monitoring, docetaxel concentration measurement, and
population pharmacokinetic modeling using NONMEM
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have been described previously [9,10]. All patients in this
retrospective study received a single intravenous dose of
75mg/m2 docetaxel. The original study found no
difference in docetaxel clearance with ethnicity; thus,
this patient population was considered a single subgroup.
Blood samples (4.5ml) for genotyping were collected in
citrated tubes and DNA was isolated using the Puregene
DNA Isolation Kit (Gentra Systems, Minneapolis,
Minnesota, USA) according to the manufacturer’s in-
structions. Genotyping of ABCC2 and SLCO1B3 poly-
morphisms was carried out at the University of California
San Francisco. The genotyping of de-identified DNA
samples was approved by the University of California San
Francisco Institutional Review Board. TaqMan SNP
genotyping was carried out for rs-12762549 (ABCC2)
and rs-11045585 (SLCO1B3). TaqMan SNP genotyping
40 primer/probe assays were purchased from Applied
Biosystems (Foster City, California, USA; ABI assay
ID numbers C_11214917_10 for rs-12762549 and
C_31106434_10 for rs-11045585). Three additional poly-
morphisms selected for strong linkage disequilibrium to
the target SNPs in Asians were also genotyped. Primers
and probes were purchased from Applied Biosystems
[ABI assay ID numbers C_31980850 for rs-11190298
(ABCC2) and C_25766123 for rs-16923270 (SLCO1B3)]
and were custom designed by Applied Biosystems for
SLCO1B3 rs-4149155
Forward primer: 50-TTGTAGGAAGAACAGAGTATATAG
GCATA-30.
Reverse primer: 50-CAGATGTATTTGATCTACTCTT
CTCTCCCTAT-30.
VIC-labeled reporter 1: 50-CAGAGGGAAGAAAGAGT-30.
FAM-labeled reporter 2: 50-ACAGAGGGAATAAAGAGT-30.
The 5 ml reactions contained 5 ng of genomic DNA,
1 TaqMan Universal Master Mix and 1 primer/probe
mix (900 nmol/l final concentration of primers and
200 mmol/l final concentration of FAM-labeled and VIC-
labeled probes). PCR and post-reads were performed on a
7900 Real-Time PCR system (Applied Biosystems, Foster
City, California. USA). Amplification conditions were
951C for 10min, followed by 40 cycles of 951C for 15 s
and 601C for 1min. Negative controls and random sample
duplicates were included on each plate for quality control
purposes. All SNPs were tested for deviation from Hardy–
Weinberg equilibrium using the w2-test. Haplotypes were
statistically inferred using the program PHASE.
The primary objective of this retrospective study was to
investigate the association of the ABCC2 polymorphism (rs-
12762549) and the SLCO1B3 polymorphism (rs-11045585)
with docetaxel clearance. The specific hypotheses, on the
basis of the results of Kiyotani et al. [8], were that carriers of
rs-12762549 or rs-11045585 have reduced docetaxel
clearance and an increased risk of neutropenia, compared
with their reference genotypes. Each hypothesis was tested
using the Wilcoxon rank-sum test at the one-sided marginal
level of 0.025. A secondary objective was to investigate the
association between drug transporter genotypes and
neutropenia. To this end, the Wilcoxon test for absolute
neutrophil count nadir and Fisher’s test for neutropenic
event (toxicity grade) were used. All secondary and
exploratory analyses were carried out using a two-sided
marginal level of 0.05 and not adjusted for multiple testing.
Ninety-nine patients were originally enrolled in CALGB
9871; of these, 64 patients had DNA samples available for
pharmacogenetic analysis with concomitant docetaxel
pharmacokinetic and neutropenia data. The demographics
of this patient subgroup are shown in Table 1. Patients with
rs-12762549 showed some evidence of reduced docetaxel
clearance compared with those patients with the reference
genotype (left panel in Fig. 1a, P=0.048), although this
did not achieve the predefined level of statistical
significance (P<0.025). There was no association between
rs-11045585 and docetaxel clearance (right panel Fig. 1a,
P=0.799). There was no association between the absolute
neutrophil count nadir and either the ABCC2 genotype
(P=0.86) or the SLCO1B3 genotype (P=0.92), Fig. 1b.
Additional analyses indicated no relationship between
these drug transporter genotypes and the occurrence
of grade 3/4 neutropenia. Three additional polymorphisms
(rs-4149155, rs-16923270, rs-11190298) were also tested for
their association with docetaxel clearance and neutropenia,
on the basis of the observation that the two tag SNPs
identified in the Kiyotani et al.’s [8] study had different
linkage disequilibrium patterns in Caucasians and African-
Americans compared with the Asian population. However,
in our study population, no association was found between
any of these SNPs and docetaxel clearance or neutropenia
Table 1 Patient demographics for CALGB 60805 (Alliance)
(a subgroup of patients from CALGB 9871: Alliance)
African-American Caucasian Total
Number of patients
enrolled
20 44 64
Median age (years) 59.5 (range
42–70)
62.5 (range
42–79)
62 (range
42–79)
Sex
Male 13 (65%) 33 (75%) 46 (72%)
Female 7 (35%) 11 (25%) 18 (28%)
Performance status
0 2 (10%) 7 (16%) 9 (14%)
1 15 (75%) 24 (55%) 39 (61%)
2 3 (15%) 12 (27%) 15 (23%)
Unknown 0 (0%) 1 (2%) 1 (2%)
Tumor types
Lung 12 (60%) 30 (68%) 42 (66%)
Breast 0 (0%) 1 (2%) 1 (2%)
GI and pancreas 3 (15%) 3 (7%) 6 (9%)
Head and neck 1 (5%) 1 (2%) 2 (3%)
Prostate 1 (5%) 1 (2%) 2 (3%)
Other 3 (15%) 8 (18%) 11 (17%)
Docetaxel dose
–75mg/m2
20 (100%) 44 (100%) 64 (100%)
Median baseline
WBC103/ml
(range)
8.9 (2.7–18.7) 6.7 (2.5–12.8) 7.0 (2.5–18.7)
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(data not shown). Post-hoc power analyses for the
SLCO1B3 polymorphism to define an odds ratio of 6 for
Z grade 3 neutropenia yielded a power of 0.84 (one sided
a=0.025); for the ABCC2 polymorphism, the power was
0.33 (one sided a=0.025) to define an odds ratio of 3 for
Z grade 3 neutropenia.
This study investigated whether the polymorphisms in
ABCC2 (rs-12762549) and in SLCO1B3 (rs-11045585)
[11,12] that were previously associated with docetaxel-
induced neutropenia in Japanese cancer patients [8] were
similarly associated with docetaxel clearance and hemato-
poietic toxicity in US Caucasian and African-American
Fig. 1
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(a) Box and whisker plots of docetaxel clearance in patients who received a single intravenous dose of 75mg/m2 of docetaxel and ABCC2
(left panel) and SLCO1B3 (right panel) genotype. The horizontal lines represent the median values of docetaxel clearance for each genotype.
For ABCC2 ?? vs CG/GG rs-12762549, the Wilcoxon–Mann–Whitney rank-sum test (P=0.048). For the SLCO1B3 AA vs AG/GG rs-11045585,
the Wilcoxon–Mann–Whitney rank-sum test (P=0.799). (b) Box and whisker plots of the nadir absolute neutrophil count (ANC) and ABCC2
rs-12762549 (left panel) and SLCO1B3 rs-11045585 (right panel) genotype. The Wilcoxon–Mann–Whitney rank-sum test (P=0.861 and 0.922)
for the ABCC2 CC vs. CG/GG and SLCO1B3 AA vs. AG/GG genotypes, respectively.
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patients enrolled in CALGB 9871. We observed decreased
docetaxel clearance in association with the ABCC2
polymorphism, but this did not result in greater neutro-
penia. Similarly, in CALGB 9871 [9], we did not establish a
pharmacokinetic–pharmacodynamic relationship for doce-
taxel-associated neutropenia. Given the findings of Kiyotani
et al. [8], this is weak evidence in support of a relationship
between the ABCC2 rs-12762549 polymorphism and
docetaxel clearance. Furthermore, our study did not
identify an association of SLCO1B3 polymorphisms with
docetaxel clearance or hematologic toxicity. To further
elucidate whether our findings may have been confounded
by the derivation of the docetaxel clearance using
population pharmacokinetics models, we added the trans-
porter genotypes to the Bruno docetaxel NONMEM
model [10], but this did not yield additional docetaxel
pharmacokinetic–drug transporter genotype associations
(data not shown). Confounding results of the association
of drug transporter polymorphisms with docetaxel pharma-
cokinetics highlight the importance of replication of
pharmacogenetic results. Baker et al. [13] studied 92 White
US and European cancer patients receiving docetaxel
therapy (at different doses, either as monotherapy or in
combination therapy) and found no relationship between
docetaxel clearance and ABCC2, SLCO1B3, or ABCB1
genotypes. The relationships between transporter genotype
and neutropenia were not explored in this study because of
the variation in the docetaxel dose used and the use of
combination chemotherapy. In a population of Asian
nasopharyngeal carcinoma patients treated with weekly
docetaxel monotherapy (n=54), an influence of functional
polymorphisms in SLCO1B3 and ABCB1 with interindivi-
dual variability in docetaxel clearance was reported [14].
Although there are conflicting reports on the association of
the ABCB1 genotype with docetaxel clearance [13–17] and
toxicity [18], the prevailing evidence does not support
a significant role for ABCB1 (P-glycoprotein) polymorph-
isms in determining docetaxel clearance.
There are a number of possible explanations why the
previous Japanese data [8] were not replicated in this
present study. Selection bias cannot be ruled out in any
retrospective study with small cohorts; furthermore, the
doses of docetaxel administered to Japanese patients
were not defined. Differences in the linkage disequili-
brium patterns for ABCC2 and SLCO1B3 were considered
in the current study and tested by the inclusion of three
additional SNPs. There was no evidence that this was the
reason for nonreplication of the previous findings in our
US population. Interestingly, the minor allele frequencies
in the study patients for rs-11045585 and rs-1276259
were 0.148 and 0.460, respectively, similar to the minor
allele frequencies in HapMap CEU Environmental
differences between study populations; variations in
treatment paradigms and concomitant medications may
all affect the phenotypes studied and therefore any
genetic associations related to drug exposures. It is not
possible to identify which one (or combination) of these
factors may have influenced the current findings. It is
possible that ongoing genome-wide association studies of
docetaxel will provide additional insights into the variable
toxicity of this agent.
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